Ataraxis AI Aims to Address Gaps in Molecular Testing with AI Digital Pathology Tests

NEW YORK – Ataraxis AI is developing artificial intelligence-driven digital pathology tests that it believes may provide faster, more accurate, and more cost-effective answers to clinical questions about cancer patients' outcomes and recurrences than traditional molecular tests on the market.